Celldex Therapeutics
CLDXCelldex Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
By net margin
Profile
Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. The company leverages its expertise in mast cell biology to create monoclonal and bispecific antibodies that engage the immune system or target critical disease pathways. Its primary objective is to address unmet medical needs in conditions where mast cell degranulation and KIT receptor activation play a central role.
Celldex is a leading developer of KIT-inhibiting antibodies, currently advancing its lead candidate through Phase 3 global clinical trials.
Questions, answered.
- What is Celldex Therapeutics's market cap?
- Celldex Therapeutics (CLDX) has a market capitalization of $2.8B and trades on NASDAQ.
- What is Celldex Therapeutics's revenue and profitability?
- Celldex Therapeutics generated $866.0K in trailing twelve-month revenue with a net loss of $283.6M, representing a net margin of -32753.6%, with free cash flow of -$226.2M. These figures are based on the Q1 2026 filing.
- Who are Celldex Therapeutics's competitors?
- Celldex Therapeutics's key competitors include AbbVie, Amgen, Eli Lilly, and others. These companies compete in similar markets and product categories.
- Who does Celldex Therapeutics partner with?
- Celldex Therapeutics's notable partners include Yale University.
- Where is Celldex Therapeutics headquartered?
- Celldex Therapeutics is headquartered in United States of America and employs approximately 160 people. It has been publicly traded since 1986.
